MOLECULAR VISION is a premier open-access journal that has been advancing the field of ophthalmology since its inception in 1995. Published by MOLECULAR VISION, this journal boasts a strong reputation, currently ranking in the second quartile (Q2) of its category, with a Scopus ranking of 35 out of 137, placing it in the 74th percentile among peer publications. Dedicated to disseminating groundbreaking research and innovative findings in the study of vision and ocular health, MOLECULAR VISION serves as a vital resource for researchers, healthcare professionals, and students engaged in this dynamic field. The journal welcomes contributions spanning fundamental and clinical research, offering a platform for crucial knowledge exchange that is essential for advancing ocular health and function. With its commitment to open access, readers around the globe can freely access and build upon the wealth of information disseminated through its pages, ensuring that the latest developments in ophthalmology are available to all.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

PROGRESS IN RETINAL AND EYE RESEARCH, published by PERGAMON-ELSEVIER SCIENCE LTD, is a premier journal dedicated to the advancement of knowledge in the fields of ophthalmology and sensory systems. With an impressive impact factor and a Q1 category ranking in both Ophthalmology and Sensory Systems as of 2023, this journal exemplifies excellence in research dissemination. Given its stature, it ranks #1 out of 137 in Ophthalmology and #1 out of 42 in Neuroscience - Sensory Systems, placing it within the top percentile of scientific publications in these domains. The journal has been actively contributing to the field since its inception in 1994 and continues to be a vital resource for researchers, clinicians, and students seeking the latest insights and breakthroughs in the understanding of retinal diseases and eye health. While it maintains a traditional subscription model, the journal remains committed to publishing high-quality, peer-reviewed articles that drive forward the frontiers of eye research and therapeutic innovation. With its strong scientific rigor and a vast array of articles, PROGRESS IN RETINAL AND EYE RESEARCH is indispensable for anyone invested in the study of visual sciences.

The Journal of the Korean Ophthalmological Society, with ISSN 0378-6471 and E-ISSN 2092-9374, is a pivotal resource in the field of ophthalmology, published by the esteemed Korean Ophthalmological Society. Based in South Korea, this journal is committed to advancing knowledge in ophthalmology through the dissemination of research that spans both clinical and experimental studies. Despite its current Q4 ranking in the 2023 Ophthalmology category, it serves as a crucial platform for emerging scholars, practitioners, and students seeking to contribute to and learn from the latest developments in eye care. While the journal does not currently offer open access, it is dedicated to fostering scientific dialogue and innovation within the community. With convergence years from 2018 to 2024, the journal's focus on contemporary issues in ophthalmology positions it as a relevant and timely source of information, critical for those engaged in this dynamic field. For further inquiries, the journal can be contacted at their address in Seoul, South Korea: SKY 1004 BLDG 701, 50-1 Jungnim-ro, Jung-gu, 04508.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, published by Springer, has established itself as a premier journal in the field of ophthalmology since its inception in 1870. With an ISSN of 0721-832X and an E-ISSN of 1435-702X, this esteemed journal enjoys a notable impact in the research community, ranking Q1 in Ophthalmology and Q1 in Sensory Systems, as per the latest 2023 journal category quartiles. GRAEFES Archive is dedicated to advancing our understanding of ocular health through both clinical and experimental studies, making it an essential resource for researchers, practitioners, and students alike. Its comprehensive scope covers various aspects of ophthalmic science, reflecting its long-standing commitment to quality and excellence. Although it currently operates on a subscription basis, the journal's significant Scopus rankings—24th out of 137 in Ophthalmology—underscore its relevance and influence within the scientific community. Situated in Germany, with its address in the United States, this international journal continues to shape the discourse on vision science and therapeutic innovation.

EXPERIMENTAL EYE RESEARCH, published by Academic Press Ltd - Elsevier Science Ltd, is a preeminent journal dedicated to advancing the fields of ophthalmology and neuroscience. With a history of insightful publications dating back to 1961, this journal serves as a critical platform for researchers, professionals, and students interested in the cellular and molecular mechanisms underlying visual processes. The journal boasts impressive rankings, including being placed in the top quartile (Q1) of both the Ophthalmology and Sensory Systems categories, and is recognized in the 2nd quartile (Q2) for Cellular and Molecular Neuroscience. With an impact factor reflecting its significant contribution to the field, EXPERIMENTAL EYE RESEARCH is a valuable resource that promotes the exchange of innovative research and ideas essential for understanding the complexities of eye function and vision-related disorders. Researchers looking to publish their findings or stay abreast of the latest studies will find this journal a vital component of their academic toolkit.